The global pharmaceutical market operates on a paradox: life-saving drugs are priced not by their therapeutic value, but by the negotiating power of the buyer. Semaglutide, sold as Ozempic for diabetes and Wegovy for obesity, exemplifies this disparity. In Canada, a generic version costs roughly 85% less than the branded drug in the United States. The reason lies in a model Britain has long championed: pharmaceutical sovereignty through price regulation and bulk procurement.
Canada’s Patented Medicine Prices Review Board caps launch prices and limits annual increases. The result is that Canadian patients pay about 87% less for semaglutide than Americans, according to a 2023 study in JAMA Internal Medicine. The U.S. price for Ozempic is approximately $900 per month without insurance; in Canada, it is around $120. For the generic, which Canada authorised in 2023 due to shortages, the price drops to under $100.
Britain’s National Health Service negotiates even more aggressively. Through the Pharmaceutical Price Regulation Scheme, the UK achieves prices among the lowest in the developed world. For Ozempic, the NHS pays about $60 per month. This model ensures access without bankrupting the health system. It is a sovereignty mechanism: a nation’s ability to determine drug prices independent of global monopoly pricing.
The United States, conversely, prohibits Medicare from negotiating drug prices, a restriction that inflates costs across the private market. The Inflation Reduction Act of 2022 introduced limited negotiation for a handful of drugs, but semaglutide is not among them until 2027. Until then, Americans continue to subsidise global pharmaceutical R&D through inflated prices.
Critics argue that price controls stifle innovation. Yet data from the UK and Canada show robust pharmaceutical R&D investment, often higher as a share of GDP than in the U.S. when accounting for public funding. The real driver of high U.S. prices is not innovation but marketing and shareholder returns. Novo Nordisk, which produces Ozempic, spends more on marketing than on research.
Environmental consequences also follow this economic disparity. High prices lead to demand for black market versions, which are often counterfeit or contaminated. The U.S. FDA has seized thousands of units of fake semaglutide laced with insulin or other compounds. These clandestine supply chains generate medical waste and energy consumption outside regulatory oversight. Conversely, regulated generics in Canada and the UK are produced under strict environmental standards.
Britain’s pharmaceutical sovereignty model, which prioritises public health over monopoly profits, is now vindicated. As obesity and diabetes epidemics strain healthcare systems globally, the ability to afford effective treatments is a matter of biosphere survival. Chronic diseases are the largest driver of healthcare emissions, from manufacturing to patient care. Lower drug costs mean better adherence, fewer complications, and reduced environmental burden.
The lesson for the United States is clear: negotiate. The mechanism exists. The political will does not. Until Americans demand that their government act like Canada or the UK, they will continue to pay the highest prices in the world for drugs that cost pennies to produce. Meanwhile, the planet watches as a proven solution remains ignored, blocked by the same forces that deny climate science: short-term profit over long-term survival.
